JP2017530127A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530127A5 JP2017530127A5 JP2017516166A JP2017516166A JP2017530127A5 JP 2017530127 A5 JP2017530127 A5 JP 2017530127A5 JP 2017516166 A JP2017516166 A JP 2017516166A JP 2017516166 A JP2017516166 A JP 2017516166A JP 2017530127 A5 JP2017530127 A5 JP 2017530127A5
- Authority
- JP
- Japan
- Prior art keywords
- nrg
- ventricular
- pharmaceutical preparation
- treating
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims description 6
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims description 6
- 101000653754 Rattus norvegicus Sphingosine 1-phosphate receptor 5 Proteins 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- ZOXZWYWOECCBSH-UHFFFAOYSA-N 4 Methyl N-ethylcathinone Chemical compound CCNC(C)C(=O)C1=CC=C(C)C=C1 ZOXZWYWOECCBSH-UHFFFAOYSA-N 0.000 claims description 3
- 102400000057 Neuregulin-2 Human genes 0.000 claims description 3
- 101800000675 Neuregulin-2 Proteins 0.000 claims description 3
- 102400000054 Neuregulin-3 Human genes 0.000 claims description 3
- 101800000673 Neuregulin-3 Proteins 0.000 claims description 3
- 101800002641 Neuregulin-4 Proteins 0.000 claims description 3
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 208000003663 ventricular fibrillation Diseases 0.000 claims 8
- 206010047302 ventricular tachycardia Diseases 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 230000008602 contraction Effects 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000002028 premature Effects 0.000 claims 3
- 230000002861 ventricular Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102400000055 Neuregulin-4 Human genes 0.000 claims 2
- 208000009729 Ventricular Premature Complexes Diseases 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 229940125794 sodium channel blocker Drugs 0.000 claims 1
- 239000003195 sodium channel blocking agent Substances 0.000 claims 1
- 108050003475 Neuregulin Proteins 0.000 description 10
- 102000014413 Neuregulin Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000012545 EGF-like domains Human genes 0.000 description 3
- 108050002150 EGF-like domains Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410529437.4 | 2014-09-24 | ||
| CN201410529437.4A CN105497876B (zh) | 2014-09-24 | 2014-09-24 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| PCT/CN2015/088972 WO2016045493A1 (zh) | 2014-09-24 | 2015-09-06 | 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530127A JP2017530127A (ja) | 2017-10-12 |
| JP2017530127A5 true JP2017530127A5 (enExample) | 2018-09-27 |
Family
ID=55580273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516166A Pending JP2017530127A (ja) | 2014-09-24 | 2015-09-06 | 心室性不整脈の予防、治療、又は遅延におけるニューレグリンの使用、及びその組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10441633B2 (enExample) |
| EP (1) | EP3199174B1 (enExample) |
| JP (1) | JP2017530127A (enExample) |
| KR (1) | KR20170055492A (enExample) |
| CN (2) | CN105497876B (enExample) |
| AU (1) | AU2015320230B2 (enExample) |
| CA (1) | CA2961813A1 (enExample) |
| RU (1) | RU2017113775A (enExample) |
| WO (1) | WO2016045493A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0620819A2 (pt) | 2005-12-30 | 2011-11-22 | Zensun Shangai Science & Technology Ltd | uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero |
| JP6096262B2 (ja) | 2009-08-25 | 2017-03-15 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | ニューレグリンに基づく心不全の治療方法 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| JP6475623B2 (ja) | 2012-10-08 | 2019-02-27 | ゼンスン（シャンハイ）サイエンス アンド テクノロジー カンパニー リミテッド | 糖尿病患者における心不全の治療用組成物 |
| CA2911848A1 (en) | 2013-05-22 | 2014-11-27 | Zensun (Shanghai) Science & Technology, Ltd. | Extended release of neuregulin for treating heart failure |
| CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| WO2020037076A1 (en) * | 2018-08-14 | 2020-02-20 | Emory University | Inducing proliferation of cardiomyocytes and therapeutic uses related thereto |
| AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| JP2022547335A (ja) * | 2019-09-16 | 2022-11-11 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | 組換えヒトニューレグリン誘導体及びその使用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115554B1 (en) | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| CA2306228A1 (en) | 1997-10-14 | 1999-04-22 | Cambridge Neuroscience, Inc. | Therapeutic methods comprising use of a neuregulin |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| CN1138785C (zh) | 1999-06-04 | 2004-02-18 | 周明东 | 生长因子神经调节蛋白及其类似物的新应用 |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| WO2003099320A1 (en) | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| CN1498656A (zh) * | 2002-11-08 | 2004-05-26 | 上海泽生科技开发有限公司 | 神经调节蛋白用于心肌梗死治疗的方法和组合物 |
| AU2006206778A1 (en) | 2005-01-20 | 2006-07-27 | Schuchean Chien | Methods for QT interval control |
| US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| BRPI0620819A2 (pt) | 2005-12-30 | 2011-11-22 | Zensun Shangai Science & Technology Ltd | uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero |
| US9580515B2 (en) | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
| CN101310766B (zh) * | 2007-05-25 | 2014-04-16 | 上海泽生科技开发有限公司 | 神经调节蛋白的新用途 |
| US20090156488A1 (en) | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| US8603817B2 (en) * | 2008-11-03 | 2013-12-10 | University Of Washington | Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling |
| EP2808339B1 (en) | 2008-11-28 | 2017-02-15 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neuregulin peptides and their use |
| WO2010060266A1 (en) | 2008-11-28 | 2010-06-03 | Zensun (Shanghai) Science & Technology Limited | Neuregulin and cardiac stem cells |
| CN102470161A (zh) | 2009-06-09 | 2012-05-23 | 上海泽生科技开发有限公司 | 神经调节蛋白用于治疗心力衰竭的有效剂量 |
| WO2010142141A1 (en) | 2009-06-09 | 2010-12-16 | Zensun (Shanghai) Science & Technology Limited | Neuregulin based methods for treating heart failure |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| EP2555788B1 (en) * | 2010-03-24 | 2017-10-11 | Massachusetts Institute of Technology | NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY. |
| US20120028992A1 (en) * | 2010-08-02 | 2012-02-02 | Brown Arthur M | Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals |
| WO2012054718A2 (en) | 2010-10-22 | 2012-04-26 | The General Hospital Corporation | Treating long qt syndrome |
| CN102302552A (zh) * | 2011-08-31 | 2012-01-04 | 朱明军 | 一种治疗心律失常的胶囊及其制备方法 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| JP6475623B2 (ja) | 2012-10-08 | 2019-02-27 | ゼンスン（シャンハイ）サイエンス アンド テクノロジー カンパニー リミテッド | 糖尿病患者における心不全の治療用組成物 |
| CA2911848A1 (en) | 2013-05-22 | 2014-11-27 | Zensun (Shanghai) Science & Technology, Ltd. | Extended release of neuregulin for treating heart failure |
| SG11201600119PA (en) | 2013-08-01 | 2016-02-26 | Gilead Sciences Inc | Compound and methods for treating long qt syndrome |
| CN104758300A (zh) | 2014-01-02 | 2015-07-08 | 上海泽生科技开发有限公司 | 维生素d及其组合物的抗菌用途 |
| CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
-
2014
- 2014-09-24 CN CN201410529437.4A patent/CN105497876B/zh active Active
-
2015
- 2015-09-06 JP JP2017516166A patent/JP2017530127A/ja active Pending
- 2015-09-06 US US15/513,939 patent/US10441633B2/en active Active
- 2015-09-06 WO PCT/CN2015/088972 patent/WO2016045493A1/zh not_active Ceased
- 2015-09-06 AU AU2015320230A patent/AU2015320230B2/en active Active
- 2015-09-06 KR KR1020177008203A patent/KR20170055492A/ko not_active Withdrawn
- 2015-09-06 CN CN201580050316.4A patent/CN110337304A/zh active Pending
- 2015-09-06 EP EP15845381.1A patent/EP3199174B1/en not_active Revoked
- 2015-09-06 CA CA2961813A patent/CA2961813A1/en not_active Abandoned
- 2015-09-06 RU RU2017113775A patent/RU2017113775A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530127A5 (enExample) | ||
| JP2014122214A5 (enExample) | ||
| EP2528616B1 (en) | Neuregulin based compositions and uses thereof for preventing or treating myocardial ischemia-reperfusion injury | |
| RU2646481C2 (ru) | Композиции и способы лечения сердечной недостаточности | |
| JP2003511071A (ja) | Ｊｎｋシグナル導入経路の細胞透過性ペプチドインヒビター | |
| EP3199174B1 (en) | Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia | |
| JP2009517055A (ja) | ニューレグリン変異体、並びにそれをスクリーニングし、及び使用する方法 | |
| US20080081785A1 (en) | Paralytic Peptide For Use In Neuromuscular Therapy | |
| JP6475623B2 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| IL204543A (en) | Use of bv8 or nucleic acid encoding bv8 to prepare a drug for the treatment of a steroid-dependent hormone disorder | |
| Boutros et al. | Alternative splicing as a mechanism for regulating 14-3-3 binding: interactions between hD53 (TPD52L1) and 14-3-3 proteins | |
| EP2480568B1 (en) | Polypeptides and nucleic acids for treating erbb2-dependent cancers | |
| ES2397327T3 (es) | Compuestos asociados a un dominio único de TDF y análogos de los mismos | |
| Karacay et al. | Expression and fine mapping of murine vasoactive intestinal peptide receptor 1 | |
| CN102443056A (zh) | 表皮生长因子受体的外显子缺失变异体 | |
| Miyabe et al. | GSP-37, a novel goldfish scale matrix protein: identification, localization and functional analysis | |
| KR101634855B1 (ko) | Trpc3와 trpc1 간의 이형복합체 형성을 저해하는 물질을 이용한 칼슘이온 관련 근육 질환의 예방 또는 치료용 조성물 | |
| JP2004041175A (ja) | ヒトｌｉｇ−１相同体（ｈｌｉｇ−１） | |
| Silva | Isomorphism, cold-adaptation, and phosphorylation of sarcomeric tropomyosin | |
| Gibbs | Calcium-binding protein interactions studied by the expression of recombinant protein | |
| JP2017125032A (ja) | 糖尿病患者における心不全の治療用組成物 | |
| CA2444594A1 (en) | Sprr1a and axonal regeneration | |
| KR100922484B1 (ko) | 인간 파필로마 바이러스 16형 단백질 ｅ6와 인터페론 조절인자 1 단백질과의 상호작용을 이용한 신생혈관생성 억제방법 | |
| Prinjha | Molecular cloning and sequence analysis of cDNAs encoding the transformation-sensitive actin cross-linking protein transgelin | |
| CN115490768A (zh) | Col1a1的表位肽及所述表位肽与热休克蛋白的复合物 |